Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Study of Adaptive Stereostactic Body Radiotherapy With Dose-escalation on the Dominant Intraprostatic Lesion for High-risk Prostate Cancer: ORION Trial Protocol

NCT07189598 is registered in ClinicalTrials.gov with Center Eugene Marquis as lead sponsor.

NCT NCT07189598
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07189598 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Study of Adaptive Stereostactic Body Radiotherapy With Dose-escalation on the Dominant Intraprostatic Lesion for High-risk Prostate Cancer: ORION Trial Protocol
Lead sponsor
Center Eugene Marquis
Phase
Not applicable
Overall status
Recruiting
Start date
March 2, 2026
Completion date
April 1, 2033
Enrollment
390 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

high risk prostate cancer